Targeted next-generation sequencing in monogenic dyslipidemias

Current Opinion in Lipidology

Volumn 26, Issue 2, 2015, Pages 103-113

  Hegele, Robert A ^a   Ban, Matthew R ^a   Cao, Henian ^a   Mcintyre, Adam D ^a   Robinson, John F ^a   Wang, Jian ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

chylomicronemia; diagnostic method; DNA mutation; familial hypercholesterolemia; next generation sequencing; whole exome sequencing; whole genome sequencing

Indexed keywords

DNA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; REAGENT;

CLINICAL EVALUATION; DIAGNOSTIC PROCEDURE; DNA SEQUENCE; DYSLIPIDEMIA; EXOME; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENE TARGETING; GENETIC SCREENING; GENOME; HIGH THROUGHPUT SEQUENCING; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; MONOGENIC DISORDER; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; REVIEW; DYSLIPIDEMIAS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; MOLECULAR DIAGNOSIS;

DYSLIPIDEMIAS; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; SEQUENCE ANALYSIS, DNA;

EID: 84945184995     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000163     Document Type: Review

References (45)

1. Hegele RA. Plasma lipoproteins: genetic influences and clinical implications. Nat Rev Genet 2009; 10:109-121.
2. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168:1-14.
3. Fouchier SW, Defesche JC, Umans-Eckenhausen MW, Kastelein JP. The molecular basis of familial hypercholesterolemia in the Netherlands. Hum Genet 2001; 109:602-615.
4. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014; 2:655-666.
5. Farhan SM, Hegele RA. Exome sequencing: new insights into lipoprotein disorders. Curr Cardiol Rep 2014; 16:507.
6. Fu J, Kwok S, Sinai L, et al. Western database of lipid variants (WDLV): a catalogue of genetic variants in monogenic dyslipidemias. Can J Cardiol 2013; 29:934-939.
7. Rahalkar AR, Hegele RA. Monogenic pediatric dyslipidemias: classification, genetics and clinical spectrum. Mol Genet Metab 2008; 93:282-294.
8. Johansen CT, Dube JB, Loyzer MN, et al. LipidSeq: A next-generation clinical resequencing panel for monogenic dyslipidemias. J Lipid Res 2014; 55:765-772.
9. Ng SB, Nickerson DA, Bamshad MJ, et al. Massively parallel sequencing and rare disease. Hum Mol Genet 2010; 19:R119-R124.
10. Nguyen L, Burnett L. Automation of molecular-based analyses: a primer on massively parallel sequencing. Clin Biochem Rev 2014; 35:169-176.
11. Rabbani B, Tekin M, Mahdieh N. The promise of whole-Exome sequencing in medical genetics. J Hum Genet 2014; 59:5-1510.
12. Koboldt DC, Steinberg KM, Larson DE, et al. The next-generation sequencing revolution and its impact on genomics. Cell 2013; 155:27-38.
13. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med 2013; 369:2369-2371.
14. Boycott KM, Vanstone MR, Bulman DE, et al. Rare-Disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet 2013; 14:681-691.
15. Rios J, Stein E, Shendure J, et al. Identification by whole-genome resequencing of gene defect responsible for severe hypercholesterolemia. Hum Mol Genet 2010; 19:4313-4318.
16. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, angptl3 mutations, and familial combined hypolipidemia. N Engl J Med 2010; 363:2220-2227.
17. Reddy MV, Iatan I, Weissglas-Volkov D, et al. Exome sequencing identifies 2 rare variants for low high-Density lipoprotein cholesterol in an extended family. Circ Cardiovasc Genet 2012; 5:538-546.
18. Marduel M, Ouguerram K, Serre V, et al. Description of a large family with autosomal dominant hypercholesterolemia associated with the ApoE p.Leu167del mutation. Hum Mutat 2013; 34:83-87.
19. Awan Z, Choi HY, Stitziel N, et al. ApoE p.Leu167del mutation in familial hypercholesterolemia. Atherosclerosis 2013; 231:218-222.
20. Cefalu AB, Pirruccello JP, Noto D, et al. A novel apoB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33:2021-2025.
21. Stitziel NO, Fouchier SW, Sjouke B, et al. Exome sequencing and directed clinical phenotyping diagnose cholesterol ester storage disease presenting as autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013; 33:2909-2914.
22. Kuivenhoven JA, Hegele RA. Mining the genome for lipid genes. Biochim Biophys Acta 2014; 1842:1993-2009.
23. Fouchier SW, Dallinga-Thie GM, Meijers JC, et al. Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. Circ Res 2014; 115:552-555.
24. Brænne I, Reiz B, Medack A, et al. Whole-Exome sequencing in an extended family with myocardial infarction unmasks familial hypercholesterolemia. BMC Cardiovasc Disord 2014; 14:108.
25. Do R, Stitziel NO, Won HH, et al. A rare variant association study with exome sequencing in >9700 early-onset myocardial infarction cases and controls. Nature 2015. (in press).
26. Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J 2013; 34:3478-3490.
27. Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Eur Heart J 2014; 35:2146-2157.
28. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180:155-160.
29. Tejedor D, Castillo S, Mozas P, et al. Comparison of DNA array platform vs DNA sequencing as genetic diagnosis tools for familial hypercholesterolemia. Clin Chem 2006; 52:1971-1972.
30. Taylor A, Patel K, Tsedeke J, et al. Mutation screening in patients for familial hypercholesterolaemia (ADH). Clin Genet 2010; 77:97-99.
31. Wright WT, Heggarty SV, Young IS, et al. Multiplex Mass ARRAY spectrometry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin Genet 2008; 74:463-468.
32. Futema M, Plagnol V, Whittall RA, et al. Use of targeted exome sequencing as a diagnostic tool for familial hypercholesterolaemia. J Med Genet 2012; 49:644-649.
33. Maglio C, Mancina RM, Motta BM, et al. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med 2014; 276:396-403.
34. Norsworthy PJ, Vandrovcova J, Thomas ER, et al. Targeted genetic testing for familial hypercholesterolaemia using next generation sequencing: a population-based study. BMC Med Genet 2014; 15:70.
35. Wang J, Ban MR, Hegele RA. Multiplex ligation-Dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia. J Lipid Res 2005; 46:366-372.
36. Faiz F, Allcock RJ, Hooper AJ, van Bockxmeer FM. Detection of variations and identifying genomic breakpoints for large deletions in the LDLR by Ion Torrent semiconductor sequencing. Atherosclerosis 2013; 230:249-255.
37. Talmud PJ, Shah S, Whittall R, et al. Use of low-Density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381:1293-1301.
38. Futema M, Plagnol V, Li K, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 2014; 51:537-544.
39. Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study. Lipids Health Dis 2011; 10:157.
40. Rahalkar AR, Giffen F, Har B, et al. Novel LPL mutations associated with lipoprotein lipase deficiency: two case reports and a literature review. Can J Physiol Pharmacol 2009; 87:151-160.
41. Babirak SP, Iverius PH, Fujimoto WY, Brunzell JD. Detection and characterization of the heterozygote state for lipoprotein lipase deficiency. Arteriosclerosis 1989; 9:326-334.
42. Myocardial Infarction Genetics Consortium Investigators. Stitziel NO, Won HH, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014; 371:2072-2082.
43. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466:707-713.
44. Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45:1274-1283.
45. Futema M, Shah S, Cooper JA. Refinement of variant selection for the LDL cholesterol genetic risk score in the diagnosis of the polygenic form of clinical familial hypercholesterolemia and replication in samples from 6 countries. Clin Chem 2015; 61:231-238.